Mupirocin and Mupirocin Calcium Formulation Producers and Market Trend

Mupirocin is an anti-bacterial ointment used to treat superficial skin infections such as impetigo caused due to bacteria such as Staphylococcus aureus and Streptococcus pyogenes.

The global Mupirocin and Mupirocin Calcium Formulation market size was USD 368 million in 2017, growing to USD 288 million in 2022, with a CAGR of -4.8% from 2017 to 2022. The global Mupirocin and Mupirocin Calcium Formulation market size is expected to reach USD 303 million in 2027, with a CAGR of 1.0% from 2022 to 2027.

Figure 2017-2027 Global Mupirocin and Mupirocin Calcium Formulation Market Size (Million USD) and CAGR

The global Mupirocin and Mupirocin Calcium Formulation market is dominated by GSK holding 30% of the market share. Other Mupirocin and Mupirocin Calcium Formulation suppliers include Glenmark Pharmaceuticals, Teva, and Sun Pharmaceutical.

Currently, APAC is the largest Mupirocin and Mupirocin Calcium Formulation production region accounting for 46% volume share, followed by comparable production in North America and Europe markets accounting for 27% and 16% volume share respectively.